Literature DB >> 33708815

Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art.

Lynn E Nooijen1, Rutger-Jan Swijnenburg1, Heinz-Josef Klümpen2, Joanne Verheij3, Geert Kazemier4, Thomas M van Gulik1, Joris I Erdmann1.   

Abstract

BACKGROUND: Surgical therapy still offers the only chance of long-term survival for patients with perihilar cholangiocarcinoma (pCCA). The aim of this narrative review is to summarize the current standards and challenges in the surgical treatment of pCCA.
SUMMARY: After imaging and defining resectability, the first step towards optimal surgical treatment is optimizing biliary drainage and preventing cholangitis, followed by securing adequate future liver remnant volume and/or function. The main goal of resection for pCCA is achieving radical resection and ultimately long-term survival. In order to achieve radical resection, several points will be addressed (e.g., vascular resection and reconstruction, intraoperative frozen sections, right versus left hemihepatectomy, and the usefulness of preoperative [chemo]therapy). KEY MESSAGES: In order to optimize long-term outcomes for patients with pCCA, collaboration between leading centers should be increased. In addition, this collaboration is necessary to design large prospective randomized controlled trials, as the incidence of pCCA is low and the number of resectable patients is even lower. Currently, most results are based on small retrospective cohort studies resulting in low evidence. In order to properly investigate how to improve long-term survival, we need to set up trials to confirm the results of small series suggesting the positive effect of preoperative chemotherapy and extended lymph node resection.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Perihilar cholangiocarcinoma; Radical resection; Surgical therapy; Survival; Vascular reconstruction

Year:  2021        PMID: 33708815      PMCID: PMC7923954          DOI: 10.1159/000514032

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  58 in total

1.  Significance of Vascular Resection and Reconstruction in Surgery for Hilar Cholangiocarcinoma: With Special Reference to Hepatic Arterial Resection and Reconstruction.

Authors:  Ryusei Matsuyama; Ryutaro Mori; Yohei Ota; Yuki Homma; Takafumi Kumamoto; Kazuhisa Takeda; Daisuke Morioka; Jiro Maegawa; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2016-07-07       Impact factor: 5.344

2.  Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma.

Authors:  S Otsuka; T Ebata; Y Yokoyama; T Mizuno; T Tsukahara; Y Shimoyama; M Ando; M Nagino
Journal:  Br J Surg       Date:  2019-03-19       Impact factor: 6.939

Review 3.  Portal vein embolization before liver resection: a systematic review.

Authors:  K P van Lienden; J W van den Esschert; W de Graaf; S Bipat; J S Lameris; T M van Gulik; O M van Delden
Journal:  Cardiovasc Intervent Radiol       Date:  2012-07-18       Impact factor: 2.740

4.  High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry.

Authors:  Pim B Olthof; Robert J S Coelen; Jimme K Wiggers; Bas Groot Koerkamp; Massimo Malago; Roberto Hernandez-Alejandro; Stefan A Topp; Marco Vivarelli; Luca A Aldrighetti; Ricardo Robles Campos; Karl J Oldhafer; William R Jarnagin; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2017-03-06       Impact factor: 3.647

5.  Extended Lymphadenectomy Versus Regional Lymphadenectomy in Resectable Hilar Cholangiocarcinoma.

Authors:  Wen-Jie Ma; Zheng-Ru Wu; Hai-Jie Hu; Jun-Ke Wang; Chang-Hao Yin; Yu-Jun Shi; Fu-Yu Li; Nan-Sheng Cheng
Journal:  J Gastrointest Surg       Date:  2019-05-30       Impact factor: 3.452

6.  Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases.

Authors:  Stefan Buettner; Jeroen L A van Vugt; Marcia P Gaspersz; Robert J S Coelen; Eva Roos; Tim A Labeur; Georgios A Margonis; Cecilia G Ethun; Shishir K Maithel; George Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley A Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Jan N M IJzermans; Thomas M van Gulik; Timothy M Pawlik; Bas Groot Koerkamp
Journal:  HPB (Oxford)       Date:  2017-05-23       Impact factor: 3.647

7.  Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma.

Authors:  Itaru Endo; Michael G House; David S Klimstra; Mithat Gönen; Michael D'Angelica; Ronald P Dematteo; Yuman Fong; Leslie H Blumgart; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2008-06-10       Impact factor: 5.344

Review 8.  Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis.

Authors:  Robert J S Coelen; Anthony T Ruys; Marc G H Besselink; Olivier R C Busch; Thomas M van Gulik
Journal:  Surg Endosc       Date:  2016-02-19       Impact factor: 4.584

Review 9.  The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.

Authors:  Zengwei Tang; Yuan Yang; Zhonghong Zhao; Kongyuan Wei; Wenbo Meng; Xun Li
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

10.  Combined Vascular Resection for Locally Advanced Perihilar Cholangiocarcinoma.

Authors:  Takashi Mizuno; Tomoki Ebata; Yukihiro Yokoyama; Tsuyoshi Igami; Junpei Yamaguchi; Shunsuke Onoe; Nobuyuki Watanabe; Yuzuru Kamei; Masato Nagino
Journal:  Ann Surg       Date:  2022-02-01       Impact factor: 12.969

View more
  2 in total

1.  Confounding by Indication Is a Major Issue in the Available Evidence on Role of Portal Vein Resection in Patients Undergoing Curative Surgery for Klatskin Tumour.

Authors:  Shahab Hajibandeh; Shahin Hajibandeh; Karim Hassan; Sumera Baloch; Thomas Satyadas
Journal:  Visc Med       Date:  2021-07-30

Review 2.  Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma.

Authors:  Su Min Cho; Abdullah Esmail; Ali Raza; Sunil Dacha; Maen Abdelrahim
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.